Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

The aim of this study was to evaluate the persistence with solifenacin therapy over a 12‐month period in patients with overactive bladder (OAB).

[1]  Tae Heon Kim,et al.  The Impact of Lower Urinary Tract Symptoms on Quality of Life, Work Productivity, Depressive Symptoms, and Sexuality in Korean Men Aged 40 Years and Older: A Population-Based Survey , 2015, International neurourology journal.

[2]  M. Palmer,et al.  Assessment of the Impact of Male Urinary Incontinence on Health‐Related Quality of Life: A Population Based Study , 2015, Lower urinary tract symptoms.

[3]  M. Burger,et al.  Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study , 2014, World Journal of Urology.

[4]  Ji Won Kim,et al.  Effect of Urgency Symptoms on the Risk of Depression in Community-Dwelling Elderly Men , 2013, Korean journal of urology.

[5]  A. Wagg,et al.  Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience , 2012, BJU international.

[6]  K. Burgio,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. , 2012, The Journal of urology.

[7]  K. Coyne,et al.  The impact of overactive bladder on mental health, work productivity and health‐related quality of life in the UK and Sweden: results from EpiLUTS , 2011, BJU international.

[8]  J. Y. Lee,et al.  Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial , 2011, International journal of clinical practice.

[9]  K. Coyne,et al.  Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature , 2011, International journal of clinical practice.

[10]  K. Coyne,et al.  Validation of the urinary sensation scale (USS) , 2011, Neurourology and urodynamics.

[11]  R. Freeman,et al.  An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction , 2010, Neurourology and urodynamics.

[12]  Seung-June Oh,et al.  Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study , 2011, World Journal of Urology.

[13]  P Michael Ho,et al.  Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.

[14]  P. Herbison,et al.  Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial , 2008, International Urogynecology Journal.

[15]  K. Coyne,et al.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study , 2008, BJU international.

[16]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[17]  Y. Homma,et al.  Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. , 2006, Urology.

[18]  F. Camacho,et al.  Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. , 2006, The Journal of urology.

[19]  C. Kelleher,et al.  The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  F. Shaya,et al.  Persistence with overactive bladder pharmacotherapy in a Medicaid population. , 2005, The American journal of managed care.

[21]  M. Nichol,et al.  Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  L. Matza,et al.  Test‐retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB‐q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) , 2005, Neurourology and urodynamics.

[23]  K. Coyne,et al.  Validation of the Urgency Perception Scale , 2005, BJU international.

[24]  B. Patel,et al.  The implications of poor medication persistence with treatment for overactive bladder. , 2004, Managed care interface.

[25]  L. Cardozo,et al.  Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. , 2004, The Journal of urology.

[26]  P. Meffan,et al.  Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder , 2004, BJU international.